The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease

Neuroscience

Volumn 228, Issue , 2013, Pages 294-300

  Duffy, A M ^a   Holscher C ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GIP; Growth factor; Insulin; Neurodegeneration; Neuron; Neuroprotection

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; INCRETIN; INSULIN RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; CELL ACTIVATION; CONTROLLED STUDY; HIPPOCAMPAL CA1 REGION; HISTOPATHOLOGY; INFLAMMATION; MACROGLIA; MALE; MOUSE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLIOSIS; INCRETINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDATIVE STRESS; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84869234340     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.10.045     Document Type: Article

References (47)

1. Aisen P.S. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 2002, 1:279-284.
2. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994, 151:1105-1113.
3. Biessels G.J., Kappelle L.J. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem Soc Trans 2005, 33:1041-1044.
4. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Munoz D.P., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012, 122:1339-1353.
5. Bozner P., Grishko V., LeDoux S., Wilson G., Chyan Y., Pappolla M. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 1997, 56:1356-1362.
6. Buhren B.A., Gasis M., Thorens B., Muller H.W., Bosse F. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J Neurosci Res 2009, 87:1858-1870.
7. Carro E., Torres A.I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490:127-133.
8. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490:127-133.
9. Cole G.M., Morihara T., Lim G.P., Yang F., Begum A., Frautschy S.A. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann N Y Acad Sci 2004, 1035:68-84.
10. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005, 26(Suppl. 1):65-69.
11. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007, 4:147-152.
12. Faivre E., Hamilton A., Holscher C. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur J Pharmacol 2012, 674:294-306.
13. Faivre E., Hölscher C. DAla2-GIP improves memory, synaptic plasticity and decreases amyloid plaques and inflammation in APP/PS1 transgenic mice 2011, AR-UK, Leeds.
14. Figueiredo C.P., Pamplona F.A., Mazzuco T.L., Aguiar A.S., Walz R., Prediger R.D. Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behav Pharmacol 2010, 21:394-408.
15. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 2003, 26:404-406.
16. Gault V.A., Holscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J Neurophysiol 2008, 99:1590-1595.
17. Gengler S., McClean P., McCurtin R., Gault V., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2012, 33:265-276.
18. Greig N.H., Mattson M.P., Perry T., Chan S.L., Giordano T., Sambamurti K., Rogers J.T., Ovadia H., Lahiri D.K. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-{alpha} inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004, 1035:290-315.
19. Hamilton A., Holscher C. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. Brain Res 2012, 1449:83-93.
20. Havrankova J., Brownstein M., Roth J. Insulin and insulin receptors in rodent brain. Diabetologia 1981, 20(Suppl.):268-273.
21. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
22. Holmes C., Cunningham C., Zotova E., Culliford D., Perry V.H. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 2011, 77:212-218.
23. Holscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 1998, 5:129-141.
24. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5:109-117.
25. Holscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 2010, 84:331-354.
26. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011, 39:891-897.
27. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004, 490:115-125.
28. Katsouri L, Vizcaychipi MP, McArthur S, Harrison I, Suarez-Calvet M, Lleo A, Lloyd DG, Ma D, Sastre M (2012) Prazosin, an alpha(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol Agingdoi:10.1016/j.neurobiolaging.2012.09.010.
29. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004, 24:10191-10200.
30. Lebovitz H.E., Banerji M.A. Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol 2004, 490:135-146.
31. Lee Y.J., Han S.B., Nam S.Y., Oh K.W., Hong J.T. Inflammation and Alzheimer's disease. Arch Pharm Res 2010, 33:1539-1556.
32. Lukiw W.J., Bazan N.G. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res 2000, 25:1173-1184.
33. McClean P., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594.
34. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010, 31:224-243.
35. Nyberg J., Anderson M.F., Meister B., Alborn A.M., Strom A.K., Brederlau A., Illerskog A.C., Nilsson O., Kieffer T.J., Hietala M.A., Ricksten A., Eriksson P.S. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 2005, 25:1816-1825.
36. Nyberg J., Jacobsson C., Anderson M.F., Eriksson P.S. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 2007, 85:2099-2119.
37. Porter D.W., Irwin N., Flatt P.R., Holscher C., Gault V.A. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol 2010, 650:688-693.
38. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940-946.
39. Steen E., Terry B.M., Rivera E., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J Alzheimers Dis 2005, 7:63-80.
40. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012, 122:1316-1338.
41. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993, 133:2861-2870.
42. Vaz A.R., Silva S.L., Barateiro A., Fernandes A., Falcao A.S., Brito M.A., Brites D. Pro-inflammatory cytokines intensify the activation of NO/NOS, JNK1/2 and caspase cascades in immature neurons exposed to elevated levels of unconjugated bilirubin. Exp Neurol 2011, 229:381-390.
43. Watson G.S., Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004, 490:97-113.
44. Xie L., Helmerhorst E., Taddei K., Plewright B., Van B.W., Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002, 22:RC221.
45. Yip R.G., Wolfe M.M. GIP biology and fat metabolism. Life Sci 2000, 66:91-103.
46. Zhao J., O'Connor T., Vassar R. The contribution of activated astrocytes to Abeta production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation 2011, 8:150.
47. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008, 22:246-260.